• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Protagenic Therapeutics, Inc. - Common Stock (NQ:PTIX)

0.7400 UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Protagenic Therapeutics, Inc. - Common Stock

News headline image
Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114
April 23, 2026
Via ACCESS Newswire
News headline image
Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114
March 17, 2026
Via ACCESS Newswire
News headline image
Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market
March 10, 2026
Via ACCESS Newswire
News headline image
Results from Phase 1 Multiple-Dose Study of PT00114
December 09, 2025
Via ACCESS Newswire
News headline image
Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study
November 13, 2025
Via ACCESS Newswire
News headline image
Protagenic Therapeutics’ Innovative Peptide PT00114 to be Highlighted at Boston Summit
April 17, 2024
Via ACCESSWIRE
News headline image
Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results
April 01, 2024
Via ACCESSWIRE
News headline image
Protagenic Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq Compliance
August 22, 2025
Via ACCESS Newswire
News headline image
Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders
August 21, 2025
Via ACCESS Newswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INZY, TXNM, SVT, PTIX on Behalf of Shareholders
May 27, 2025
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. (Nasdaq – INZY), TXNM Energy, Inc. (NYSE - TXNM), Servotronics, Inc. (NYSE American - SVT), Protagenic Therapeutics, Inc. (Nasdaq – PTIX)
May 27, 2025
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders
March 27, 2024
Via ACCESSWIRE
News headline image
Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity
May 21, 2025
Via ACCESS Newswire
News headline image
PTIX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Protagenic Therapeutics, Inc. Is Fair to Shareholders
May 19, 2025
From Halper Sadeh LLC
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. (Nasdaq – INZY), TXNM Energy, Inc. (NYSE - TXNM), Servotronics, Inc. (NYSE American - SVT), Protagenic Therapeutics, Inc. (Nasdaq – PTIX)
May 19, 2025
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call
March 25, 2024
Via ACCESSWIRE
News headline image
Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders
February 13, 2024
Via ACCESSWIRE
News headline image
Protagenic Therapeutics Initiates Phase I/IIa Clinical Trial for Groundbreaking Brain Peptide PT00114
September 26, 2023
Via ACCESSWIRE
News headline image
Protagenic Therapeutics and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company with Six Drug Candidates in Development including Treatments for Obesity and Metabolic Disorders
May 19, 2025
Via ACCESS Newswire
News headline image
Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split
April 29, 2025
Via ACCESS Newswire
News headline image
Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
November 05, 2024
Via ACCESSWIRE
News headline image
Protagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric Disorders
May 22, 2024
Via ACCESSWIRE
News headline image
Protagenic Therapeutics to Effect 1-for-4 Reverse Stock Split
March 22, 2023
Via ACCESSWIRE
News headline image
Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial
May 01, 2024
Via ACCESSWIRE
News headline image
Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice
March 21, 2024
Via ACCESSWIRE
News headline image
Protagenic Therapeutics to Present at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference on April 27th
April 26, 2022
NEW YORK, NY / ACCESSWIRE / April 26, 2022 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing drug product candidates to treat stress-related neurologic... 
From Protagenic Therapeutics, Inc.
Via AccessWire
News headline image
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
July 08, 2021
RALEIGH, NC / ACCESSWIRE / July 8, 2021 / Access to Giving - an investor conference themed around investor education and advocacy begins next week, July 13th - 15th, 2021. More than 50 companies are... 
From Access to Giving
Via AccessWire
News headline image
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021
June 23, 2021
RALEIGH, NC / ACCESSWIRE / June 23, 2021 / Access to Giving - an investor conference themed around investor education and advocacy is set for July 13-15, 2021. There will be 50+ companies conducting... 
From Access to Giving
Via AccessWire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap